MiRus’s $1.5B raise in May 2026 was one of the month’s largest deals in any sector — and a striking reminder that medical devices can still command megaround capital in an AI-obsessed market.

The problem this startup is attacking

Implantable devices depend on materials science. MiRus develops advanced alloys and implant technologies to improve durability, biocompatibility, and outcomes across spine, cardiac, and orthopedic applications.

Why this is a live problem now

• Aging populations drive sustained implant demand.
• Materials innovation can meaningfully improve patient outcomes.
• The reopening exit market improves medtech funding appetite.

Competitive map

• Large device incumbents (Medtronic, Stryker, Zimmer Biomet).
• Specialized materials and implant startups.

Market signal (the number to remember)

• $1.5B — a megaround scale rare for medtech, signaling deep conviction in MiRus’s materials platform.

Practical takeaway (operator + investor)

MiRus shows venture’s biggest checks aren’t only for AI. Hard medtech with differentiated materials and clinical validation can still raise at scale. Founders should lead with regulatory progress and outcomes; investors should keep medtech on the radar.

Sources

1. Crunchbase News (MiRus among largest May rounds): https://news.crunchbase.com/venture/monthly-vc-funding-recap-ai-may-2026/